Ms. Jennifer CHE, J.D., Vice President and Principal of Eagle IP Limited, shared about the unique IP challenges biomedical innovations in the GBA and China face. She demonstrated how a strategic approach to IP is crucial – especially at the earliest stages – to avoiding messy issues down the road. She finally touched upon what unique role Hong Kong can play to help protect and cultivate future important biomedical inventions arising out of the GBA and China.
Our Past Events
Recommended Insights
How will Civil Cases Work under the Patent Linkage Provision in the New Chinese Patent Law?
20 November 2020The Supreme People’s Court has just issued draft regulations for comment regarding how new Article 76 will work in conjunction with civil procedure law. The period to submit comments ends December 14, 2020, and the final version will come into force June 1, 2021, together with the new Chinese Patent Law. The Backdrop: New Chinese […]
Read more >
CNIPA further clarifies how it counts “delays” when calculating Patent Term Adjustment (PTA) in the new Draft Examination Guidelines and how it affects international applicants
12 April 2023At the end of October 2022, the China National Intellectual Property Administration (CNIPA) released a new draft amendment of the Patent Examination Guidelines1 (hereinafter referred to as the “New Draft”) to the new Chinese Patent Law that came into effect in 2021. We highlight two key amendments below. 1. The starting date for calculating PTA […]
Read more >
2020 China Top 10 IP Cases: Winners’ Sun is truly a Winner: A Simple Selfie-Stick Utility Model Patent Crushes Infringers in China
2 August 2021Each year The Intellectual Property Tribunal of the Supreme People’s Court releases a list of top 10 technical intellectual property rights court case decisions. The 2020 list came out a few months ago, and we have been highlighting some of these cases. Today, we will cover a utility model patent infringement case. As one of […]
Read more >
China Top 10 Cases of 2020 – CNIPA Upholds Second Medical Use Patent from University of Bordeaux
24 May 2021The development of China’s approach to patents, especially those in the pharmaceutical and biotech space, has been fascinating to watch. Those of us who have practiced in the area for a long time have been frustrated by the Chinese patent office’s overly strict rules regarding patentability (e.g., high data support standard and refusal to consider […]
Read more >